Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
Isabel ÁlvarezS BezaresE Dalmau PortulasE García-MartínezJ Á García-SáenzM Gil-GilE Martínez de DueñasN RibellesA Santaballa BertránPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
We have developed a consensus document with recommendations on the treatment of patients with HER2-negative luminal MBC that will help to improve therapeutic benefits.